Biostax Corp.
BTAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.75K
Close$
Share Statistics
| Market cap | $16,754.00 |
|---|---|
| Enterprise Value | $2.44 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.03 |
| Beta | 0.72 |
| Outstanding Shares | 83,770,337 |
Return
| Return on Equity | -17.61% |
|---|---|
| Return on Assets | 17134.47% |
| Return on Invested Capital | -15.82% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 2.91 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.99 |
| Debt to Equity | -0.46 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biostax Corp.
4 employees
CEO: Noreen Griffin Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug cand...